First Invasive BCI for Patients Enters Clinical Use; Market Eyes $904M

For healthcare providers and payers, the arrival of a commercial invasive BCI device disrupts traditional rehabilitation paradigms. This system translates brain signals to hand movement for spinal cord injury patients, but its real-world impact hinges on reimbursement policy, neurosurgical training, and post-market safety surveillance—areas where health systems must act swiftly.

China's brain-computer interface (BCI) sector has crossed a critical threshold, transitioning from laboratory research to clinical reality with the market launch of the world's first invasive BCI medical device. The National Medical Products Administration (NMPA) approved the innovative product registration for Neuracle Technology's implantable hand motor function compensation system, specifically designed for patients with tetraplegia from cervical spinal cord injury. This device—comprising an implant, electrode kit, signal transceiver, pneumatic glove, and associated software—enables hand grasping function through decoded neural signals, a tangible breakthrough that sets a precedent for the global neurotechnology industry.

“

CCID Consulting, under the Ministry of Industry and Information Technology, projects the domestic BCI market will reach 6.14 billion yuan (approximately $904.3 million) by 2028, growing at a compound annual rate of 17.7% from 2024.

This milestone is part of a broader acceleration in China's BCI ecosystem throughout the first half of 2026. Multiple companies are on track to complete patient enrollment for invasive and semi-invasive BCI clinical trials within the year, signaling a maturing pipeline. CCID Consulting, under the Ministry of Industry and Information Technology, projects the domestic BCI market will reach 6.14 billion yuan (approximately $904.3 million) by 2028, growing at a compound annual rate of 17.7% from 2024. These figures underscore the strategic importance Beijing places on BCI technology, officially designated a "future industry" for long-term development.

The Neuracle device's approval marks more than a regulatory win—it represents the convergence of clinical demand, engineering innovation, and favorable policy. The product's multi-component design injects new possibilities into neurorehabilitation, a field long limited by insufficient treatment options for severe paralysis. For patients, the immediate benefit is a degree of functional independence; for the healthcare system, it introduces a new device class requiring surgical implantation, software integration, and long-term patient monitoring.

Investment and clinical infrastructure are ramping in tandem. Industry insiders note that expanding clinical resources and improving reimbursement mechanisms will be decisive for BCI adoption in real-world settings. Without adequate coverage, these high-cost devices risk remaining accessible only to a privileged few, blunting their public health impact. China's national insurance framework has yet to codify BCI-specific reimbursement, but the NMPA categorization as an innovative medical device may accelerate health technology assessment and coverage decisions, drawing parallels to earlier orphan device pathways in other jurisdictions.

Globally, China's progression puts competitive pressure on Western BCI developers such as Neuralink and Synchron, who are navigating their own regulatory and clinical hurdles. China's centralized regulatory model and large patient pool could enable faster real-world evidence generation, potentially tipping the balance in commercialization timelines. However, invasive approaches raise safety, data security, and ethical questions that will necessitate rigorous post-market surveillance.